ContentsInnovationNew biopolymersFashion demands betterRegulation & policyTrump’s overhaulA new EU bioeconomy ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...

The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...

Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...

The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...

Climate-resilient agriculture uses biotechnology, biofertilizers, biopesticides, genome-edited crops, and AI-driven tools to ...

Chennai: Central Bureau of Investigation (CBI) has booked city-based rice mill owners and an office bearer on charges of ...

Issued on behalf of Avant Technologies Inc.VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- USA News Group News Commentary – Recent clinical trials achieving ...

A competitor's setback was Xeris Biopharma 's ( XERS +7.39%) gain on Hump Day. On news that a potential commercial threat to ...

Health-care companies fell, but not by as much as the broad market, amid optimism about the outlook for drug sales next year. Eli Lilly and Novo Nordisk are likely to see strong demand for pill forms ...

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...